Cardiovascular diseases (CVD) of atherosclerotic genesis still remain the leading cause of death and disability among the population of many countries of the world. The key to reducing the risk of developing cardiovascular complications and adverse outcomes in patients with CVD is the control of cardiovascular risk factors. The article discusses the prevalence and significance of CVD risk factors. A significant increase in the prevalence of such CVD risk factors as type 2 diabetes and overweight/obesity is emphasized. In real clinical practice, doctors are faced with various disorders of lipid metabolism. Dyslipidemia is recognized as a leading risk factor for atherosclerosis. Therapeutic targets of lipid-lowering therapy, optimal values of lipid parameters depending on the risk category, issues of lipid-lowering therapy are discussed. The mechanisms of action of statins and fibrates have been disclosed. The strategy of combined lipid-lowering therapy is considered as a way to reduce residual risk. Simplification of therapeutic regimens using a fixed combination of rosuvastatin and fenofibrate increases patient adherence to treatment and its outcome.

Keywords: fixed combination, fenofibrate, rosuvastatin, type 2 diabetes mellitus, dyslipidemia, cardiovascular disease, atherosclerosis